Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level.

Muralidhar V, Nguyen PL, Mahal BA, Yang DD, Mouw KW, Rose BS, Beard CJ, Efstathiou JA, Martin NE, King MT, Orio PF.

J Natl Compr Canc Netw. 2019 Aug 1;17(8):941-948. doi: 10.6004/jnccn.2018.7283.

PMID:
31390585
2.

Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.

Abu Zaid M, Dinh PC, Monahan PO, Fung C, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Sesso HD, Huddart R, Mushiroda T, Kubo M, Dolan ME, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group.

J Natl Compr Canc Netw. 2019 May 1;17(5):459-468. doi: 10.6004/jnccn.2018.7109.

PMID:
31085753
3.

Exophytic Mass Arising Within Hidradenitis Suppurativa: Challenge.

Beard CJ, Gathings RM, Bandino JP.

Am J Dermatopathol. 2019 Mar;41(3):e26. doi: 10.1097/DAD.0000000000001065. No abstract available.

PMID:
30802225
4.

Exophytic Mass Arising Within Hidradenitis Suppurativa: Answer.

Beard CJ, Gathings RM, Bandino JP.

Am J Dermatopathol. 2019 Mar;41(3):235-236. doi: 10.1097/DAD.0000000000001064. No abstract available.

PMID:
30801344
5.

Excisional Biopsy.

Beard Cj, Schmieder GJ.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2018 Nov 23.

6.

Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer.

King MT, Nguyen PL, Boldbaatar N, Tempany CM, Cormack RA, Beard CJ, Hurwitz MD, Suh WW, D'Amico AV, Orio PF 3rd.

Cancer. 2018 Sep 1;124(17):3528-3535. doi: 10.1002/cncr.31568. Epub 2018 Jul 5.

7.

Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce.

Dinh KT, Aizer AA, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL.

Am J Med. 2018 May;131(5):517-523. doi: 10.1016/j.amjmed.2017.11.039. Epub 2018 Mar 16.

PMID:
29555248
8.

Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score.

Feldman DR, Ardeshir-Rouhani-Fard S, Monahan P, Sesso HD, Fung C, Williams AM, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Zaid MA, Lipshultz SE, Einhorn LH, Oeffinger KC, Travis LB, Fossa SD; Platinum Study Group.

Clin Genitourin Cancer. 2018 Aug;16(4):e761-e769. doi: 10.1016/j.clgc.2018.01.011. Epub 2018 Feb 5.

9.

Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors.

Zaid MA, Gathirua-Mwangi WG, Fung C, Monahan PO, El-Charif O, Williams AM, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse SK, Ardeshir-Rouhani-Fard S, Dinh PC, Sesso HD, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group.

J Natl Compr Canc Netw. 2018 Mar;16(3):257-265. doi: 10.6004/jnccn.2017.7046.

10.

Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70.

Kamran SC, Seisen T, Markt SC, Preston MA, Trinh QD, Frazier LA, Choueiri TK, Martin NE, Nguyen PL, Beard CJ.

Eur Urol. 2018 Apr;73(4):e96-e97. doi: 10.1016/j.eururo.2017.12.026. Epub 2018 Jan 19. No abstract available.

PMID:
29358058
11.

Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70.

Seisen T, Kamran SC, Markt SC, Preston MA, Trinh QD, Frazier LA, Choueiri TK, Martin NE, Nguyen PL, Beard CJ.

Eur Urol. 2018 Apr;73(4):e100-e101. doi: 10.1016/j.eururo.2017.10.013. Epub 2017 Nov 3. No abstract available.

PMID:
29108659
12.

Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy.

Yang DD, Muralidhar V, Mahal BA, Beard CJ, Mouw KW, Martin NE, Orio PF 3rd, King MT, Nguyen PL.

Am J Clin Oncol. 2018 Oct;41(10):953-959. doi: 10.1097/COC.0000000000000410.

PMID:
29045266
13.

Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer.

Yang DD, Mahal BA, Muralidhar V, Boldbaatar N, Labe SA, Nezolosky MD, Vastola ME, Beard CJ, Martin NE, Mouw KW, Orio PF 3rd, King MT, Nguyen PL.

Cancer. 2017 Dec 15;123(24):4832-4840. doi: 10.1002/cncr.30948. Epub 2017 Aug 22.

14.

Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.

Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF 3rd, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL.

Eur Urol Focus. 2019 Jan;5(1):69-76. doi: 10.1016/j.euf.2017.05.011. Epub 2017 Jun 17.

PMID:
28753811
15.

Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience.

Kamran SC, Harshman LC, Bhagwat MS, Muralidhar V, Nguyen PL, Martin NE, La Follette S, Faso S, Viswanathan AN, Efstathiou JA, Beard CJ.

Adv Radiat Oncol. 2017 Jan 17;2(2):140-147. doi: 10.1016/j.adro.2017.01.001. eCollection 2017 Apr-Jun.

16.

Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer.

Kamran SC, Seisen T, Markt SC, Preston MA, Trinh QD, Frazier LA, Choueiri TK, Martin NE, Nguyen PL, Beard CJ.

Eur Urol. 2018 Feb;73(2):262-270. doi: 10.1016/j.eururo.2017.06.013. Epub 2017 Jul 4.

PMID:
28687143
17.

Quantifying Decreased Radiation Exposure From Modern CT Scan Technology and Surveillance Programs of Germ Cell Tumors.

Howard SA, Rosenthal MH, Qin L, Matalon SA, Bernard BD, Beard CJ, Sweeney CJ.

Am J Clin Oncol. 2018 Oct;41(10):949-952. doi: 10.1097/COC.0000000000000399.

PMID:
28654572
18.

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.

Dolan ME, El Charif O, Wheeler HE, Gamazon ER, Ardeshir-Rouhani-Fard S, Monahan P, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kim J, Fossa SD, Hertz DL, Mushiroda T, Kubo M, Einhorn LH, Cox NJ, Travis LB; Platinum Study Group.

Clin Cancer Res. 2017 Oct 1;23(19):5757-5768. doi: 10.1158/1078-0432.CCR-16-3224. Epub 2017 Jun 13.

19.

Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer.

Muralidhar V, Mahal BA, Rose BS, Chen YW, Nezolosky MD, Efstathiou JA, Beard CJ, Martin NE, Orio PF 3rd, Trinh QD, Choueiri TK, Sweeney CJ, Nguyen PL.

Clin Genitourin Cancer. 2017 Oct;15(5):563-569.e3. doi: 10.1016/j.clgc.2016.10.011. Epub 2016 Oct 28.

PMID:
28462857
20.

Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.

Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL.

Ann Oncol. 2017 May 1;28(5):1098-1104. doi: 10.1093/annonc/mdx041.

PMID:
28453693
21.

Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.

Fung C, Sesso HD, Williams AM, Kerns SL, Monahan P, Abu Zaid M, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Kollmannsberger CK, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Lipshultz SE, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group.

J Clin Oncol. 2017 Apr 10;35(11):1211-1222. doi: 10.1200/JCO.2016.70.3108. Epub 2017 Feb 27.

22.

Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer.

Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, Orio PF, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng FY.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):186-192. doi: 10.1038/pcan.2016.58. Epub 2017 Jan 24.

23.

Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity.

Wheeler HE, Gamazon ER, Frisina RD, Perez-Cervantes C, El Charif O, Mapes B, Fossa SD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kollmannsberger C, Kim J, Mushiroda T, Kubo M, Ardeshir-Rouhani-Fard S, Einhorn LH, Cox NJ, Dolan ME, Travis LB.

Clin Cancer Res. 2017 Jul 1;23(13):3325-3333. doi: 10.1158/1078-0432.CCR-16-2809. Epub 2016 Dec 30.

24.

National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?

Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL.

Cancer. 2016 Nov 15;122(21):3371-3377. doi: 10.1002/cncr.30205. Epub 2016 Jul 19.

25.

Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer.

Chen YW, Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Choueiri TK, Hoffman KE, Martin NE, Orio PF, Sweeney CJ, Feng FY, Trinh QD, Nguyen PL.

Brachytherapy. 2016 Nov - Dec;15(6):695-700. doi: 10.1016/j.brachy.2016.07.001. Epub 2016 Aug 12.

PMID:
27528590
26.

Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors.

Markt SC, Lago-Hernandez CA, Miller RE, Mahal BA, Bernard B, Albiges L, Frazier LA, Beard CJ, Wright AA, Sweeney CJ.

Cancer. 2016 Oct 15;122(20):3127-3135. doi: 10.1002/cncr.30159. Epub 2016 Aug 8.

27.

Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.

Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, Monahan PO, Feldman DR, Hamilton R, Vaughn DJ, Beard CJ, Budnick A, Johnson EM, Ardeshir-Rouhani-Fard S, Einhorn LH, Lipshultz SE, Dolan ME, Travis LB.

J Clin Oncol. 2016 Aug 10;34(23):2712-20. doi: 10.1200/JCO.2016.66.8822. Epub 2016 Jun 27.

28.

Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer.

Muralidhar V, Catalano PJ, Reznor G, Mahal BA, Choueiri TK, Sweeney CJ, Martin NE, Beard CJ, Chen YW, Nezolosky MD, Hoffman KE, Feng FY, Trinh QD, Nguyen PL.

J Natl Compr Canc Netw. 2016 Apr;14(4):421-8.

PMID:
27059190
29.

Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer.

Muralidhar V, Xiang M, Orio PF 3rd, Martin NE, Beard CJ, Feng FY, Hoffman KE, Nguyen PL.

J Contemp Brachytherapy. 2016 Feb;8(1):1-6. doi: 10.5114/jcb.2016.58080. Epub 2016 Feb 29.

30.

Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer.

Chen YW, Mahal BA, Muralidhar V, Nezolosky M, Beard CJ, Den RB, Feng FY, Hoffman KE, Martin NE, Orio PF, Nguyen PL.

Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):683-90. doi: 10.1016/j.ijrobp.2015.12.008. Epub 2015 Dec 14.

31.

National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study.

Mahal BA, Chen YW, Efstathiou JA, Muralidhar V, Hoffman KE, Yu JB, Feng FY, Beard CJ, Martin NE, Orio PF 3rd, Nguyen PL.

Cancer. 2016 May 15;122(10):1505-12. doi: 10.1002/cncr.29960. Epub 2016 Mar 11.

32.

Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.

Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, Feng FY, Hoffman KE, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL.

Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):828-35. doi: 10.1016/j.ijrobp.2015.07.2281. Epub 2015 Jul 29.

33.

Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012.

Nezolosky MD, Dinh KT, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL.

Urol Oncol. 2016 Feb;34(2):57.e15-22. doi: 10.1016/j.urolonc.2015.09.002. Epub 2015 Oct 23.

PMID:
26476663
34.

Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ‚Č•50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?

Dinh KT, Muralidhar V, Mahal BA, Chen YW, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL.

Urology. 2016 Jan;87:125-32. doi: 10.1016/j.urology.2015.08.026. Epub 2015 Sep 21.

PMID:
26391387
35.

Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer.

Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Feng FY, Martin NE, Efstathiou JA, Choueiri TK, Pomerantz MM, Sweeney CJ, Trinh QD, Vander Heiden MG, Nguyen PL.

BJU Int. 2016 Aug;118(2):279-85. doi: 10.1111/bju.13248. Epub 2015 Aug 31.

36.

Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach.

Beard CJ, Gupta S, Motzer RJ, O'Donnell EK, Plimack ER, Margolin KA, Ryan CJ, Sheinfeld J, Feldman DR.

J Natl Compr Canc Netw. 2015 Jun;13(6):811-22. Review.

PMID:
26085395
37.

Secondary malignant neoplasms in testicular cancer survivors.

Curreri SA, Fung C, Beard CJ.

Urol Oncol. 2015 Sep;33(9):392-8. doi: 10.1016/j.urolonc.2015.05.002. Epub 2015 Jun 11. Review.

PMID:
26072728
38.

Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer.

Muralidhar V, Mahal BA, Ziehr DR, Chen YW, Nezolosky MD, Viswanathan VB, Beard CJ, Devlin PM, Martin NE, Orio PF 3rd, Nguyen PL.

Brachytherapy. 2015 Jul-Aug;14(4):511-6. doi: 10.1016/j.brachy.2015.03.004. Epub 2015 Apr 14.

PMID:
25887342
39.

Risk of prostate cancer mortality in men with a history of prior cancer.

Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL.

BJU Int. 2016 Jun;117(6B):E20-8. doi: 10.1111/bju.13144. Epub 2015 May 23.

40.

Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer.

Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL.

J Urol. 2015 Aug;194(2):343-9. doi: 10.1016/j.juro.2015.02.015. Epub 2015 Feb 11.

PMID:
25681290
41.

Who bears the greatest burden of aggressive treatment of indolent prostate cancer?

Mahal BA, Cooperberg MR, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Orio PF 3rd, Trinh QD, Nguyen PL.

Am J Med. 2015 Jun;128(6):609-16. doi: 10.1016/j.amjmed.2014.12.030. Epub 2015 Jan 30.

42.

Incidence and determinants of 1-month mortality after cancer-directed surgery.

Mahal BA, Inverso G, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hoffman KE, Hu JC, Beard CJ, D'Amico AV, Martin NE, Orio PF 3rd, Trinh QD, Nguyen PL.

Ann Oncol. 2015 Feb;26(2):399-406. doi: 10.1093/annonc/mdu534. Epub 2014 Nov 27.

PMID:
25430935
43.

Income inequality and treatment of African American men with high-risk prostate cancer.

Ziehr DR, Mahal BA, Aizer AA, Hyatt AS, Beard CJ, D Amico AV, Choueiri TK, Elfiky A, Lathan CS, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL.

Urol Oncol. 2015 Jan;33(1):18.e7-18.e13. doi: 10.1016/j.urolonc.2014.09.005. Epub 2014 Oct 11.

PMID:
25306287
44.

Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor.

Howard SA, Gray KP, O'Donnell EK, Fennessy FM, Beard CJ, Sweeney CJ.

AJR Am J Roentgenol. 2014 Oct;203(4):W415-20. doi: 10.2214/AJR.13.11615.

PMID:
25247970
45.

Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.

Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Basaria SS, Beard CJ, Beckman JA, Choueiri TK, D'Amico AV, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL.

BJU Int. 2015 Sep;116(3):358-65. doi: 10.1111/bju.12905. Epub 2014 Oct 29.

46.

The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act.

Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Lago-Hernandez C, Chen YW, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Trinh QD, Nguyen PL.

Prostate Cancer Prostatic Dis. 2014 Sep;17(3):273-9. doi: 10.1038/pcan.2014.23. Epub 2014 Jul 1.

PMID:
24980272
47.

Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups.

Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Sammon JD, Schmid M, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL.

Urology. 2014 Aug;84(2):386-92. doi: 10.1016/j.urology.2014.05.009. Epub 2014 Jun 26.

PMID:
24975710
48.

Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results.

Mahal BA, Ziehr DR, Hyatt AS, Neubauer-Sugar EH, O'Farrell DA, O'Leary MP, Steele GS, Niedermayr TR, Beard CJ, Martin NE, Orio PF, D'Amico AV, Devlin PM, Nguyen PL.

Brachytherapy. 2014 Sep-Oct;13(5):442-9. doi: 10.1016/j.brachy.2014.05.001. Epub 2014 May 28.

PMID:
24880584
49.

Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer.

Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Lago-Hernandez C, Choueiri TK, Elfiky AA, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Lathan CS, Trinh QD, Nguyen PL.

J Geriatr Oncol. 2014 Oct 1;5(4):352-8. doi: 10.1016/j.jgo.2014.05.001. Epub 2014 May 23.

PMID:
24862107
50.

Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer.

Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Hoffman KE, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL.

Clin Genitourin Cancer. 2014 Oct;12(5):e189-95. doi: 10.1016/j.clgc.2014.04.003. Epub 2014 May 9.

PMID:
24861952

Supplemental Content

Loading ...
Support Center